$9.5M Eagle Pharmaceuticals Securities Class Action Settlement (EGRX)

What Changed Recently?

The settlement is now approved. The court granted final approval and entered judgment on August 19, 2026, the same day as the fairness hearing. That is the development that matters most to a class member who has not filed: nothing further stands between the settlement and distribution except the appeal period, claims processing, and the October 16 deadline.

The case got there quickly by securities-litigation standards, because it settled before the pleadings were resolved. The complaint was filed December 11, 2023. The court appointed lead plaintiff and lead counsel on August 19, 2024. On October 2, 2024, Eagle filed a Form 8-K stating that its financial statements dating back to the quarter ended June 30, 2022 should no longer be relied upon and should be restated — the event that closed the class period the day before. The amended complaint followed on July 11, 2025, and the defendants moved to dismiss it on August 25, 2025.

That motion was never decided. The parties had mediated for a full day on April 29, 2025 without reaching agreement, but the mediator kept working with them, and on September 30, 2025 both sides accepted her double-blind proposal of $9,500,000. A term sheet followed on November 5, 2025. Before signing the long-form agreement the plaintiffs took informal discovery: between December 8, 2025 and January 29, 2026 the defendants produced roughly 115,000 pages, including accounting memos, customer contracts, board materials and documents on Pemfexy's shelf life, projected demand and customer inventories. The Stipulation was executed March 13, 2026, preliminary approval came in May 2026, and notice went out on June 18, 2026.

One small discrepancy is worth knowing if you are comparing documents: the settlement website dates preliminary approval to May 20, 2026, while paragraph 28 of the court-approved notice dates it to May 18, 2026. Nothing turns on it — neither date affects any deadline a class member has to meet.

None of this is a finding against anyone. The defendants have denied and continue to deny all allegations of fault, liability, wrongdoing or damages, and say they settled solely to eliminate the uncertainty, burden and expense of further litigation.

What the Case Alleged

The action claimed violations of Section 10(b) of the Securities Exchange Act of 1934 and SEC Rule 10b-5 against Eagle Pharmaceuticals, Inc. and two of its officers, Scott Tarriff and Brian Cahill, plus control-person claims under Section 20(a) against the two individuals.

The amended complaint alleged that the defendants made materially misleading statements and omitted material facts about how much of Eagle's revenue came from sales of Pemfexy, its version of the cancer drug pemetrexed, in the second quarter of 2022, and about whether the company's internal controls over financial reporting were effective. It alleged that the share price was artificially inflated as a result, and fell when the truth emerged.

The defendants argued in their motion to dismiss that the complaint failed on every element that mattered: that it did not plead scienter, because it alleged no motive to defraud, leaned on unproven allegations from an unadjudicated complaint in another lawsuit, and identified nobody at Eagle who believed the accounting was wrong when it was issued; that it did not identify an actionable misstatement, because it never specified which internal controls were ineffective and the financial statements were honestly held opinions; and that it did not plead loss causation, because none of the cited disclosures revealed the alleged fraud.

The court never ruled on any of it. These are allegations that were never tested, all defendants deny them, and no court has found any defendant liable.